Welcome to our dedicated page for 60 Degrees Pharm news (Ticker: SXTPW), a resource for investors and traders seeking the latest updates and insights on 60 Degrees Pharm stock.
60 Degrees Pharmaceuticals Inc. (SXTPW) is a clinical-stage company developing innovative therapies for infectious diseases, notably malaria prophylaxis through its FDA-approved product ARAKODA. This page serves as the definitive source for official company announcements, research milestones, and regulatory developments.
Investors and healthcare professionals will find timely updates on clinical trials, partnership agreements, and therapeutic advancements. Our curated collection includes press releases covering drug development progress, peer-reviewed research findings, and strategic initiatives in tropical medicine.
Key content areas include malaria prevention updates, babesiosis treatment research, FDA regulatory communications, and collaborative studies with academic institutions. All materials are sourced directly from company filings and verified channels to ensure reliability.
Bookmark this page for streamlined access to SXTPW's latest developments in infectious disease therapeutics. Check regularly for updates on pipeline innovations and clinical trial data impacting global health outcomes.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) opened the central site at Mount Sinai Icahn School of Medicine to enroll patients in the B-FREE Chronic Babesiosis Study on Nov 21, 2025.
The Phase 2 open-label study (NCT06656351) will evaluate an ARAKODA® (tafenoquine) regimen over 90 days for resolution of severe fatigue and parasite eradication, will run ~12 months, and plans to enroll up to 100 patients. Internal estimates put the U.S. unmet need between 4,400 and 190,000 cases annually; a study aim is to confirm Babesia infection using validated molecular tests to refine market size. Tafenoquine is approved for malaria prophylaxis as ARAKODA® but is not approved or proven for babesiosis treatment.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) reported Q3 2025 results for the quarter ended September 30, 2025. Net product revenue rose 223% YoY to $438,000 and ARAKODA pharmacy deliveries increased 14% to 1,505 boxes. The company recorded a gross loss of ~$100,000 versus a $24,000 gross profit a year earlier due to a one-time inventory write-off tied to short shelf-life validation lots. Operating expenses were ~$2.32 million, driven by an additional $367,000 in advertising and sales promotion. Net loss attributable to common shareholders was approximately $2.44 million or ($0.66) per share. New four-year shelf-life lots are expected to enter the supply chain in early Q1 2026.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) reported that the first patient completing its expanded access study of ARAKODA® (tafenoquine) for relapsing babesiosis tested negative for Babesia by both a Mayo Clinic RT-PCR and an FDA-licensed RNA amplification assay that is described as at least 100x more sensitive than standard RT-PCR.
On October 3, 2025 the company submitted a Breakthrough Therapy request to FDA and plans a Type B meeting in early 2026 to discuss requirements for a supplementary NDA; remaining patients are expected to finish between January and October 2026 and clinical data are expected in second half of 2026.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) named its chronic babesiosis Phase 2 trial the B-FREE Chronic Babesiosis Study (NCT06656351). The open-label study will begin in early November and run for approximately 12 months, testing a 90-day ARAKODA® (tafenoquine) regimen for resolution of severe fatigue and parasite eradication in chronic babesiosis. No FDA-approved or society-recommended treatment for chronic babesiosis currently exists. The company donated $5,000 split between Global Lyme Alliance and ILADEF after a patient-driven naming contest.
60 Degrees Pharmaceuticals (NASDAQ: SXTP), a pharmaceutical company focused on vector-borne disease treatments, has announced an updated schedule for their presentation at the H.C. Wainwright 27th Annual Global Investment Conference. The presentation will now take place on Tuesday, September 9, 2025, at 3:30 PM ET at the Lotte New York Palace Hotel.
CEO Dr. Geoff Dow will deliver a live presentation, and the management team will be available for one-on-one meetings during the conference. The presentation will be accessible via webcast for interested investors.
60 Degrees Pharmaceuticals (NASDAQ:SXTP), a company focused on developing medicines for vector-borne diseases, will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, at the Lotte New York Palace Hotel.
CEO Dr. Geoff Dow will deliver a live presentation on September 10 at 2:30 ET. Management will also conduct one-on-one meetings during the conference. The presentation will be available via webcast with replay access for approximately 90 days on the company's investor relations website.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) has selected the Icahn School of Medicine at Mount Sinai as the central site for a Phase II clinical trial evaluating tafenoquine for chronic babesiosis treatment. The 90-day open-label study will assess the drug's efficacy in treating patients with disabling fatigue lasting at least six months.
The trial will evaluate ARAKODA® (tafenoquine) with a dosing regimen of 2 x 100 mg tablets administered orally for the first four days, followed by weekly doses for 12 weeks. The primary endpoint is fatigue resolution measured using a patient-reported outcome scale. Enrollment is expected to begin in Q4 2025 with completion targeted for Q2 2026.
This study is one of three clinical trials sponsored by 60 Degrees Pharma to evaluate tafenoquine for babesiosis, with data expected in H1 2026. The company plans to submit a New Drug Application (NDA) to the FDA in 2026.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) reported Q2 2025 financial results, highlighting a 19% year-over-year decline in net product revenues to $101,000 due to a temporary supply chain disruption. Despite lower revenues, the company achieved increased profitability with a gross profit of $51,000, up from $35,000 in Q2 2024.
Operating expenses decreased significantly to $1.86 million from $4.22 million in Q2 2024. The net loss improved to $1.84 million ($1.25 per share) compared to $4.29 million ($21.12 per share) in Q2 2024. With $1.97 million cash on hand and recent public offering proceeds of $4.46 million, the company projects runway through March 31, 2026.
Research studies indicate the total addressable U.S. market for ARAKODA for human babesiosis could reach $1.1 billion over the remaining 10-year patent life, with annual babesiosis incidence estimated between 25,000-380,000 cases.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) has entered into a research agreement with Tulane University to study tafenoquine's effectiveness against Borrelia (Lyme disease) and Bartonella bacteria in cell culture. These pathogens, along with Babesia, are known as the "3Bs" commonly found in tick-borne illnesses.
The study aims to evaluate tafenoquine, an FDA-approved antimalarial drug marketed as ARAKODA®, for potential treatment of co-infections in babesiosis patients. Currently, tafenoquine is undergoing babesiosis trials at several sites. The drug's safety for malaria prophylaxis has been validated through six randomized, controlled trials lasting up to 12 months, though it remains unapproved for treating babesiosis, Borrelia, or Bartonella infections.
60 Degrees Pharmaceuticals (NASDAQ:SXTP) has closed its previously announced public offering, raising $5 million in immediate gross proceeds. The offering consists of 2,631,578 shares of common stock (or pre-funded warrants) with accompanying Series A-1 and A-2 warrants at $1.90 per share.
The offering includes Series A-1 warrants with a 5-year term and Series A-2 warrants with an 18-month term, both with an exercise price of $1.90 per share. If the Series A-2 warrants are fully exercised, the company could receive up to an additional $5 million in gross proceeds. H.C. Wainwright & Co. served as the exclusive placement agent, and the proceeds will be used for working capital and general corporate purposes.
FAQ
What is the current stock price of 60 Degrees Pharm (SXTPW)?
